Page 273«..10 20..272273274 275..280 290..»

Skin Disorders: Pictures, symptoms, causes and help – TODAY – TODAY

By daniellenierenberg

Is it acne, a rash or maybe something more serious? Skin disorders can vary in both symptoms and severity. Some skin conditions are minor, some are serious but treatable, and others, like skin cancer, can be life-threatening. Here are 18 common (and a few less common) skin conditions with photos to help you ID them. Remember to always reach out to your physician for a proper diagnosis and treatment.

Suffering from acne? Youre not alone. Acne is the most common condition dermatologists treat 40 to 50 million Americans struggle with acne at any given time.

Acne can show up almost anywhere on the skin as blackheads, papules and pustules or pimples, cysts and nodules

Acne starts when dead skin cells dont shed properly and clog your pores.

Some acne can be treated with over-the-counter products, while others require professional help, including prescription medication and treatments.

Read more about acne and how to treat it.

These precancerous lesions often appear as rough spots on the skin. Actinic keratosis is common, but if left untreated it can turn into squamous cell carcinoma.

The appearance of actinic keratosis can vary from bumps that look like pimples or acne to rough lesions that are red, pink or gray.

When cells in the skin called keratinocytes are damaged by UV rays, it can cause actinic keratosis.

While not always necessary, treatments may include removal of the actinic keratosis with liquid nitrogen, chemical peels, scraping or other therapies.

Read more about actinic keratosis and how to treat it.

Basal cell carcinoma is the most common type of skin cancer. It affects approximately 2.6 million people in the U.S. each year. Do you know how to spot it?

Basal cell carcinoma is much more common in people who have light skin. Symptoms tend to be the same color as the skin or pink. Its important to look for any changes in your skin.

Exposure from ultraviolet rays (UV) from the sun or indoor tanning is a primary cause of basal cell carcinoma.

Your dermatologist may be able to remove a basal cell carcinoma tumor when doing a biopsy. Sometimes a Mohs surgery is recommended.

Read more about basal cell carcinoma and how to spot it.

A common skin condition, most people develop blisters once in a while.

Blisters are small, painful sacs of fluid.

Blisters can be caused by friction, such as by a shoe rubbing against the skin, or by sunburns, heat or skin diseases.

Blisters tend to heal on their own, but a blister can be drained if its too painful.

Read more about blisters and how to treat them.

Sometimes confused with a spider bite, a carbuncle is a group of boils that stem from an infection of the skin and are connected to each other.

Red, tender bumps, or boils, that contain pus are signs of a carbuncle. Carbuncles can eventually rupture, and pus will leak out of them.

A bacterial infection, such as Staphylococcus aureus, is often the cause of a carbuncle.

If a carbuncle is small, you may be able to treat it at home with warm compresses and bandages. Otherwise, your dermatologist can make an incision to drain the pus.

Read more about carbuncles and how to treat them.

Cellulitis is an infection of the skin in which the skin becomes red and swollen. It typically occurs after you get a cut or wound.

When you have cellulitis, an area of your skin often on one of your legs becomes red, swollen, warm and possibly painful.

Cellulitis can be caused by two different types of bacteria: streptococcus (aka strep) or staphylococcus (aka staph).

Antibiotics like penicillin, cephalosporin or erythromycin are normally used to treat cellulitis.

Read more about cellulitis and how to treat it.

Also called varicella, this highly contagious disease mostly strikes children.

A fever may precede it, but the unique chicken pox rash appears on the skin with itchy blisters that look like lots of little dew drops.

The varicella-zoster virus (VZV) causes chicken pox as well as shingles. Its unlikely to get chicken pox if youve had the chicken pox vaccine.

The best treatment for chicken pox is prevention through vaccination. An early case of chicken pox may be treated with antiviral drugs. Other remedies can be used to ease symptoms.

Read more about chicken pox and how to treat it.

Trending stories,celebrity news and all the best of TODAY.

Also known as fever blisters, cold sores are blisters, or clusters of blisters, that appear on your lips or near your mouth.

Symptoms of cold sores can vary. The sores may start with a tingling, burning or other sensation, then break open and scab over.

Cold sores are caused by the herpes simplex virus. Outbreaks are triggered by stress, fatigue, illness and other factors.

Read more about cold sores and how to treat them.

Almost everyone gets contact dermatitis at some point. There are two main types of contact dermatitis allergic and irritant. Both trigger a rash.

Symptoms of allergic contact dermatitis may include itching, rash, dryness and other symptoms. Cracked, itchy, chapped skin with sores may be signs of irritant contact dermatitis.

Contact dermatitis is caused by something that touches your skin like poison ivy, nickel, fragrances, latex or other irritants and triggers a rash.

The best treatment for contact dermatitis is to avoid whatever it is that triggers your rash. Beyond that, your dermatologist may also recommend antihistamine pills, moisturizers or topical steroids.

Read more about contact dermatitis and how to treat it.

Eczema is a condition that causes red, itchy patches on the skin. It often starts at a young age often people with eczema get it when they're babies.

Eczema is almost always itchy, but otherwise symptoms can vary from person to person. Skin infected with eczema can be dry, dark, scaly, swollen or oozing.

Eczema may be caused by an overactive immune system, but its not entirely clear what causes the condition.

There is no cure for eczema, but symptoms can be managed with medications and other therapies.

Read more about eczema and how to treat it

The onset of hives can be mysterious, and though hives usually go away in less than 24 hours, new ones can repeatedly appear.

Hives appear on the skin as slightly swollen, raised pink or red patches. You may have one hive, a group of hives that may be separate or connected together.

Its difficult to pinpoint the cause of hives, but there are many triggers that can cause hives, from insect bites and allergic reactions to medication, stress and heat.

The go-to treatment for hives is usually antihistamines.

Read more about hives and how to treat them.

People with an allergy to latex are allergic to a protein found in the sap of the Brazilian rubber tree.

Different symptoms appear with different types of latex allergies. One type causes a rash on the skin; another can cause anaphylaxis, which can result in a swelling of the airways and difficulty breathing.

When your immune system reacts as though latex is a harmful substance, it causes an allergic reaction to latex.

Since theres no cure for latex allergies, your best bet is to avoid coming into contact with latex.

Read more about latex allergy and how to treat it.

An autoimmune disease that causes pain and inflammation, lupus can affect your skin, as well as your kidneys, heart, joints and lungs.

A red butterfly-shaped rash that appears on the nose and cheeks is one common sign of lupus, but symptoms of lupus will vary, depending on the type of lupus you have.

There are a number of factors that may play a role in whether you develop rosacea, but experts dont know for certain what causes the skin condition.

There is no cure for rosacea, but the condition can be managed to help keep symptoms from worsening.

Read more about lupus and how to treat it.

Also known as rubeola, measles is a contagious and potentially deadly disease that usually strikes children.

Beyond the signifying red, spotted rash, measles may also be accompanied by a fever, cough, runny nose and other symptoms.

A virus that infects the respiratory tract and spreads throughout the body causes measles. Its one of the most contagious diseases.

The best treatment is prevention through a vaccine. Otherwise, high doses of vitamin A, bed rest and medications to reduce pain and fever may help.

Read more about measles and how to treat it.

Its one of the less common skin cancers, but melanoma is the most dangerous because it can easily spread to other parts of your body.

Melanoma tumors tend to be black or brown, but can sometimes be pink, tan or white. Anyone can get melanoma, but people with light skin are at greater risk.

UV light exposure from ultraviolet rays from the sun or indoor tanning causes most melanomas.

Treatments depend on how advanced the melanoma is and where the tumor is located. It may include surgery, radiation, chemotherapy or other therapies.

Read more about melanoma and how to treat it.

Psoriasis affects more than 8 million people in the U.S. It typically starts in the teen years or early 20s, though it can occur at any age.

When you have psoriasis, your body makes new skin cells quickly, and the cells typically build up in thick, scaly patches on the skin called plaques.

There are a number of factors that may contribute to causing psoriasis. The immune system and genetics may play a role. Certain triggers can also cause the onset of psoriasis and psoriasis flare-ups.

Psoriasis doesnt have a cure, there are medications and treatments that can help manage the condition.

Read more about psoriasis and how to treat it.

This common inflammatory skin condition causes redness of the face.

In addition to causing facial redness, if rosacea is not treated, it can cause visible blood vessels, breakouts like acne and other symptoms.

There are a number of factors that may play a role in whether you develop rosacea, but experts dont know for certain what causes the skin condition.

There is no cure for rosacea, but the condition can be managed to help keep symptoms from worsening.

Read more about rosacea and how to treat it.

Also known as cutaneous squamous cell carcinoma, this cancer develops when the squamous cells in the top layer of your skin grow out of control.

Though its linked with exposure to ultraviolet rays, squamous cell carcinoma can crop up in areas that dont get much sun. Watch out for rough, scaly patches, sores that dont heal or anything else that looks suspicious.

Squamous cell carcinoma is mainly caused by UV rays from the sun or indoor tanning.

Treatments for squamous cell carcinoma may include surgery, radiation or other therapies. Catching it early is key.

Read more about squamous cell carcinoma and how to treat it.

Read the original:
Skin Disorders: Pictures, symptoms, causes and help - TODAY - TODAY

Skin Stem Cells commento

Comments Off | data

August 13th, 2020

IN CASE YOU MISSED ITSchedule of Reuters features from this week – Reuters

By daniellenierenberg

Aug 13 (Reuters) - Every week, Reuters journalists produce scores of multimedia features and human-interest stories from around the world.

Below are some engaging stories selected by our editors, as well as explanatory context and background on world headlines. For a full schedule of news and events, please go to our editorial calendar on Reuters Connect here

Baby George, born amid Beirut blast, is light in the darkness

BEIRUT, Aug 12 - Stepping into the delivery room where his wife Emmanuelle was about to give birth, Edmond Khnaisser meant to capture their sons first moments on camera. Instead, he recorded the instant the biggest blast in Lebanons history sent windows crashing onto the hospital bed. (LEBANON-SECURITY/BLAST-BABY (TV, PIX), moved, 401 words)

Squeegee selfies: Tel Aviv tower-washer is rising TikTok star

TEL AVIV, Aug 11 - Twirling to hip hop over chasms of steel and glass, soapy squeegee in one hand and a smartphone in the other, Noa Toledo is an Israeli social media star who aims to encourage other women to take on her traditionally male-dominated job. (ISRAEL-SOCIALMEDIA/WINDOW WASHER (TV, PIX), moved, 155 words)

From carats to peanuts: how a pandemic upended the global diamond industry

JOHANNESBURG/MUMBAI, Aug 12 - As the coronavirus pandemic shuttered mines from Lesotho to Canada and disrupted supply chains, Rajen Patel swapped diamond polishing for peanut farming. (HEALTH-CORONAVIRUS/DIAMONDS (PIX, GRAPHICS), by Helen Reid, Tanisha Heiberg and Rajendra Jadhav, 828 words)

Raphael did a nose-job in self-portrait, face reconstruction suggests

ROME, Aug 11 - Raphael probably didnt like his nose, and replaced it with an idealised version in his famous self-portrait. (ARTS-ITALY/RAPHAEL (PIX, TV), by Philip Pullella, 399 words)

Back from the dead? Stem cells give hope for revival of Malaysias extinct rhinos

KUANTAN, Malaysia, Aug 12 - Some skin, eggs and tissue samples are all that remain of Malaysias last rhino, Iman, who died last November after years of failed breeding attempts. (MALAYSIA-WILDLIFE/RHINO (TV, PIX), by Joseph Sipalan, 517 words)

Dream destination cafes offer taste of paradise in blockaded Gaza strip

GAZA, Aug 11 - Mediterranean waves crash below patrons snacking on freshly-caught fish at the Maldive Gaza cafe, offering a glimpse of paradise to Palestinians confined to the blockaded strip. (PALESTINIANS-GAZA/MALDIVES (TV, PIX), by Nidal al-Mughrabi, 207 words)

Virtually identical: Grounded Japanese try foreign holidays with a difference

TOKYO, Aug 12 - Japanese businessman Katsuo Inoue chose Italy for this years summer vacation, and he enjoyed the trimmings of a business class cabin and soaked up the sights of Florence and Rome - without ever leaving Tokyo. (HEALTH CORONAVIRUS/JAPAN-VR TRAVEL (TV, PIX), by Akira Tomoshige, 296 words)

For the art collector with everything, the $1.5 million COVID mask

MOTZA, Israel, Aug 12 - Art rather than ostentation is the rationale behind the worlds most expensive coronavirus mask, say the Israeli jewellers who are crafting the $1.5 million object for an unnamed U.S.-based client. (HEALTH-CORONAVIRUS/ISRAEL-MASK (TV, PIX), moved, 234 words)

Coping with campus coronavirus: U.S. fraternities, sororities give it the old college try

MADISON, Wisconsin, Aug 12 - Sixteen gallons of hand sanitizer sat in the foyer of the Alpha Epsilon Phi sorority house at the University of Wisconsin as house mother Karen Mullis reconfigured tables in the dining room to maintain social distancing. (HEALTH-CORONAVIRUS/FRATERNITIES-SORORITIES (PIX, GRAPHIC), by Brendan OBrien, 754 words)

Some U.S. colleges stick to in-person reopening in pandemic despite doubts, pushback

Aug 11 - Many U.S. universities are revamping campuses to resume in-person classes despite COVID-19, drawing criticism from some college town residents and critics who say schools are putting profits before public safety. (HEALTH-CORONAVIRUS/UNIVERSITIES (PIX, TV, GRAPHIC), by Jan Wolfe and Catherine Koppel, 729 words)

EXPLAINER-The U.S. push to extend U.N. arms embargo on Iran

Where Biden and Trump stand on key issues (tmsnrt.rs/3iDd4YG)

FACTBOX-Who is speaking at the Democratic National Convention - and why

NEWSMAKER-How Kamala Harris found the political identity that had eluded her

FACTBOX-Political crisis unfolds in Belarus after presidential vote

EXPLAINER-Microsofts TikTok bid spotlights Windows makers history with China

FACTBOX-Who is Jimmy Lai, the media tycoon arrested in Hong Kong?

FACTBOX-How financial firms in Hong Kong may be affected by U.S. sanctions

UNDERSTANDING COVID-19

EXPLAINER-When will a coronavirus vaccine be ready?

FACTBOX-World reaction to Russias COVID-19 vaccine

FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines

GRAPHIC-U.S. COVID-19 deaths drop for first time in four weeks (tmsnrt.rs/2WTOZDR)

The Lifeline Pipeline: the drugs, tests and tactics that may conquer coronavirus (reut.rs/3bhMUaE)

Coronavirus and the global economy (tmsnrt.rs/3cg7OXF)

The new normal: How far is far enough? (tmsnrt.rs/3dKqnnn)

Prominent people diagnosed with COVID-19

Global tracker (tmsnrt.rs/2W82n73)

U.S. tracker (tmsnrt.rs/2ySIhG0) (Compiled by Leela de Kretser, Patrick Enright and Tiffany Wu)

Follow this link:
IN CASE YOU MISSED ITSchedule of Reuters features from this week - Reuters

Skin Stem Cells commento

Comments Off | data

August 13th, 2020

Back From the Dead? Stem Cells Give Hope for Revival of Malaysia’s Extinct Rhinos – The New York Times

By daniellenierenberg

KUANTAN, Malaysia Some skin, eggs and tissue samples are all that remain of Malaysia's last rhino, Iman, who died last November after years of failed breeding attempts.

Now scientists are pinning their hopes on experimental stem cell technology to bring back the Malaysian variant of the Sumatran rhinoceros, making use of cells from Iman and two other dead rhinos.

"I'm very confident," molecular biologist Muhammad Lokman Md Isa told Reuters in his laboratory at the International Islamic University of Malaysia.

"If everything is functioning, works well and everybody supports us, it's not impossible."

The smallest among the world's rhinos, the Sumatran species was declared extinct in the wild in Malaysia in 2015. Once it had roamed across Asia, but hunting and forest clearance reduced its numbers to just 80 in neighbouring Indonesia.

Iman, 25, died in a nature reserve on Borneo island, following massive blood loss caused by uterine tumours, within six months of the death of Malaysia's last male rhino, Tam.

Efforts to get the two to breed had not worked.

"He was the equivalent of a 70-year-old man, so of course you don't expect the sperm to be all that good," said John Payne of the Borneo Rhino Alliance (BORA), who has campaigned for about four decades to save Malaysia's rhinos.

"It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos in Indonesia. But right till today, Indonesia is still not keen on this."

ACROSS THE BORDER

Indonesia's environment ministry disputed accusations of cross-border rivalry as a reason why Malaysia's rhinos died out, saying talks continue on ways to work with conservationists in the neighbouring southeast Asian nation.

"Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country," said Indra Exploitasia, the ministry's director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which number just two. Researchers in that effort reported some success in 2018 in producing embyronic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Thomas Hildebrandt and Cesare Galli, the scientists leading the research.

And even if it worked, the animals' lack of genetic diversity could pose a threat to long-term survival, Galli told Reuters.

Indonesian scientist Arief Boediono is among those helping in Malaysia, hoping success will provide lessons to help his country's rhinos.

"It may take five, 10, 20 years, I don't know," Arief added. "But there has already been some success involving lab rats in Japan, so that means there is a chance."

Japanese researchers have grown teeth and organs such as pancreas and kidneys using embryonic stem cells from rats and mice in efforts to grow replacement human organs.

For now, however, Iman's hide will be stuffed and put on display alongside Tam in a Borneo museum.

(Editing by Matthew Tostevin and Clarence Fernandez)

Originally posted here:
Back From the Dead? Stem Cells Give Hope for Revival of Malaysia's Extinct Rhinos - The New York Times

Skin Stem Cells commento

Comments Off | data

August 12th, 2020

Beauty & Wellness Awards 2020: New Kids on the Block – Prestige Online

By daniellenierenberg

After months of reviewing close to 300 beauty products and wellness facilities, and tallying, here are the best skincare products of this year, and lest we forget, your top pick! And so without further ado, here are the Beauty & Wellness Awards winners.

As technology continues to advance and discoveries are made each day,we do our part in dipping our toe in the proverbial pool of beauty toexplore the latest and greatest. Embracing the new is part of our job asinvestigative beauty aficionados, and as we dig through the recentdebuts, weve found some newbies that have found a permanent spot onour top shelf that we highly recommend checking out.

Best Face Cream: First Aid Beauty Ultra Repair Cream

For even the most sensitive skin, FAB delivers animpressive amount of hydration without anyirritation. The luscious whipped-cream texturespreads easily over the face, yet still holds wellenough for make-up to sit over nicely.

Ultra Repair Cream

HK$249/170g; HK$109/56.7G

Best Hydrating Serum: Skin Need 100% Hyaluronic Acid B5

The ultimate water magnet, thisserum locks in all the hydration youneed. Its easily absorbed, so yourskin feels fresh and clean without atrace of stickiness. The heavy doseof hyaluronic acid binds and trapsmoisture to the skin.

100% Hyaluronic Acid B5

HK$598

Best Reparative Formula: Wildsmith Skin Active Repair Radiance Polisher

Exfoliate to your hearts content and skinsneed the gentle grains of walnut shell androsehip-seed powder sloughs away deadskin cells and polishes the skins surface. Mixthe desired amount with any facial cleanserto create your very own scrub.

Skin Active Repair Radiance Polisher

HK$254

Best Body Cream: Augustinus Bader The Body Cream

A fresh launch from world-leadingstem cell and biomedical pioneerand scientist, Professor AugustinusBader, The Body Cream is officiallythe newest must-have item in bodyand skin care. Powered by thebrands patented Trigger FactorComplex (TFC8), this cellularrenewal cream reawakens dormantstem cells and results in firmer,toned skin with a reduction incellulite and stretch marks.

Readers Choice: Drunk Elephant F-balm

Electrolytes pump us full of hydration. And if its good to ingest. Why wouldnt it be topically? This waterfacial masque hydratant nourishes and repairs parched skin while you sleep. Its cooling effects are especially appreciated this season.

All of the Drunk Elephant products are naturally formulated and cater directly to your skins health. Oi Tak Kan, Prestige Reader

Skin Stem Cells commento

Comments Off | data

August 12th, 2020

Going On At The Greenville Library – WSPA 7News

By daniellenierenberg

No roars at Augusta as Masters to be played without fansNews / 12 mins ago

1 dead, 1 injured in deputy-involved shooting in Anderson Co., K-9 shot and killedNews / 20 mins ago

Going On At The Greenville LibraryEntertainment / 1 hour ago

Work It Wednesday - Skin UndertonesEntertainment / 2 hours ago

It's back to the future or forward to the past on National Vinyl Record DayEntertainment / 2 hours ago

Wellness By Design - Help With Joint Pain Using Stem CellsEntertainment / 2 hours ago

Jamarcus Tells Us What He Has Been Up To In York County SCEntertainment / 2 hours ago

Race is on to make COVID-19 changes for November electionNews / 4 hours ago

Carolina Morning Weather Aug. 12Weather / 6 hours ago

'Put forth a little bit of effort': Greenville County Schools Superintendent talks virtual learning dress codeNews / 12 hours ago

Bentley tries taking PAC-12 shutdown in strideSports / 14 hours ago

HSRZ Team Preview: Wade Hampton GeneralsSports / 14 hours ago

See the original post:
Going On At The Greenville Library - WSPA 7News

Skin Stem Cells commento

Comments Off | data

August 12th, 2020

Stem Cell Grafts Show Functionality in Spinal Cord Injuries

By daniellenierenberg

In mouse studies, the specialized grafts integrated with host networks and behaved much like neurons in a healthy, undamaged spinal cord.

Using stem cells to restore lost functions due to spinal cord injury (SCI) has long been an ambition of scientists and doctors. Nearly 18,000 people in the United States suffer SCIs each year, with another 294,000 persons living with an SCI, usually involving some degree of permanent paralysis or diminished physical function, such as bladder control or difficulty breathing.

In a new study, published August 5, 2020 in Cell Stem Cell , researchers at University of California San Diego School of Medicine report successfully implanting highly specialized grafts of neural stem cells directly into spinal cord injuries in mice, then documenting how the grafts grew and filled the injury sites, integrating with and mimicking the animals existing neuronal network.

Until this study, said the studys first author Steven Ceto, a postdoctoral fellow in the lab of Mark H. Tuszynski, MD, PhD, professor of neurosciences and director of the Translational Neuroscience Institute at UC San Diego School of Medicine, neural stem cell grafts being developed in the lab were sort of a black box.

Although previous research, including published workby Tuszynski and colleagues, had shown improved functioning in SCI animal models after neural stem cell grafts, scientists did not know exactly what was happening.

We knew that damaged host axons grew extensively into (injury sites), and that graft neurons in turn extended large numbers of axons into the spinal cord, but we had no idea what kind of activity was actually occurring inside the graft itself, said Ceto. We didnt know if host and graft axons were actually making functional connections, or if they just looked like they could be.

Ceto, Tuszynski and colleagues took advantage of recent technological advances that allow researchers to both stimulate and record the activity of genetically and anatomically defined neuron populations with light rather than electricity. This ensured they knew exactly which host and graft neurons were in play, without having to worry about electric currents spreading through tissue and giving potentially misleading results.

They discovered that even in the absence of a specific stimulus, graft neurons fired spontaneously in distinct clusters of neurons with highly correlated activity, much like in the neural networks of the normal spinal cord. When researchers stimulated regenerating axons coming from the animals brain, they found that some of the same spontaneously active clusters of graft neurons responded robustly, indicating that these networks receive functional synaptic connections from inputs that typically drive movement. Sensory stimuli, such as a light touch and pinch, also activated graft neurons.

We showed that we could turn on spinal cord neurons below the injury site by stimulating graft axons extending into these areas, said Ceto. Putting all these results together, it turns out that neural stem cell grafts have a remarkable ability to self-assemble into spinal cord-like neural networks that functionally integrate with the host nervous system. After years of speculation and inference, we showed directly that each of the building blocks of a neuronal relay across spinal cord injury are in fact functional.

Tuszynski said his team is now working on several avenues to enhance the functional connectivity of stem cell grafts, such as organizing the topology of grafts to mimic that of the normal spinal cord with scaffolds and using electrical stimulation to strengthen the synapses between host and graft neurons.

While the perfect combination of stem cells, stimulation, rehabilitation and other interventions may be years off, patients are living with spinal cord injury right now, Tuszynski said. Therefore, we are currently working with regulatory authorities to move our stem cell graft approach into clinical trials as soon as possible. If everything goes well, we could have a therapy within the decade.

Co-authors of the study are Kohel J. Sekiguchi and Axel Nimmerjahn, Salk Institute for Biological Studies and Yoshio Takashima, UC San Diego and Veterans Administration Medical Center, San Diego.

Funding for this research came, in part, from Wings for Life, the University of California Frontiers of Innovation Scholars Program, the Veterans Administration (Gordon Mansfield Spinal Cord Injury Collaborative Consortium, RR&D B7332R), the National Institutes of Health (grants NS104442 and NS108034), The Craig H. Neilsen Foundation, the Kakajima Foundation, the Bernard and Anne Spitzer Charitable Trust and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.

Source: Scott LaFee, UC San Diego School of Medicine

Posted on August 5th, 2020 in Uncategorized.

See the article here:
Stem Cell Grafts Show Functionality in Spinal Cord Injuries

Spinal Cord Stem Cells commento

Comments Off | data

August 12th, 2020

Repairing damage caused by spinal cord injury with stem cells

By daniellenierenberg

Although spinal cord injuries (SCI) are not as prevalent as other debilitating conditions, they can be particularly devastating. Patients often lose motor control and sensibility and require assistance with everyday tasks. Most people are familiar with the case of Christopher Reeve, an American actor who played Superman in the 70s and 80s. He suffered a cervical spinal cord injury and was left paralyzed from the neck down. Reeve became an advocate for research into a potential cure using stem cells.

The World Health Organization estimates that every year up to 500,000 people suffer this type of injury worldwide. In Canada, approximately 85,000 people are currently living with some type of SCI.

The possibility of repairing damage sustained by the spinal cord is one of the most exciting potential applications of regenerative medicine. There have been promising advancements in this field and it is just a matter of time before they give way to actual treatments. Access to these treatments is just one of the many advantages of cell banking.

Inside the spinal column, which runs from the base of the skull to the coccyx, lies a fragile structure made up of nervous tissue. This is the spinal cord. Its job is to carry nerve signals from the brain to the rest of the body.

The spinal cord is very delicate and while it is protected by the vertebrae, it can easily be damaged either by trauma or disease. Injuries are graded according to their severity on a scale designed by the American Spinal Injury Association (ASIA) that goes from A to E (A being a complete injury, where all motor and sensory function is lost. E represents normal function). The severity of the injury is inversely correlated with the probability of recovery. According to the American Association of Neurological Surgeons, nearly half of all spinal cord injuries are complete.

In addition to the physical damage, spinal cord injuries are incredibly challenging in psychological terms. The more severe the injury, the more likely it is that the individual will lose the ability to care for himself. As reported in Mayo Clinic Proceedings, adults with spinal cord injury are at a higher risk of developing mental health disorders. Additionally, the rate of suicide increases three-fold among patients with this type of injury compared to the general population.

In a study published in Topics in Spinal Cord Injury Rehabilitation, researchers from the University of Alabama analyzed data from patients that sustained spinal cord injuries from 2005 to 2011. They found that automobile crashes (31.5% of cases) and falls (25.3%) account for more than half of all incidents. Other common causes are gunshot wounds, motorcycle crashes, and diving accidents. Although not frequent, diseases can cause spinal cord injury as well, specifically cancer, and osteoporosis.

Considering all causes, men account for 8 out of every 10 cases of spinal cord injury. Additionally, according to the Mayo Clinic, people are more likely to suffer traumatic cord injuries between the ages of 16 and 30. Avoiding risky behavior is the most effective strategy for preventing spinal cord injury.

In addition to the ASIA scale, which ranks injury by the severity of the damage, spinal cord injuries can be classified depending on the area affected. There are four types of spinal cord injury: cervical, thoracic, lumbar, and sacral.

The uppermost portion of the spine (vertebrae C1 to C7) is called the cervical section. Traumatic cord injuries in this area can lead to quadriplegia or full paralysis. This is the sort of injury that actor Christopher Reeve sustained. He shattered his C-1 and C-2 vertebrae in a horseback riding accident. Baseball player Roy Campanella damaged his C-5 and C-6 vertebrae in an automobile accident.

The thoracic spine is comprised of 12 vertebrae (T-1 to T-12) and it is located below the cervical section. An injury to this area could result in loss of use of the chest, upper back, and abdominals.

The lumbar section of the spine is located in the lower back. It comprises five vertebrae (L1 to L5). An injury to this area can leave an individual paraplegic, unable to move or feel anything below the point of injury. Deng Pufang, son of Chinas former leader Deng Xiaoping, suffered a lumbar spinal cord injury and became paralyzed.

The sacral section is located between the lumbar section and the coccyx. Injury to this area may cause loss of function in the hips and legs. Bladder function may be compromised as well. Injuries to this section of the spine are less common than cervical, thoracic, or lumbar injuries.

A discovery made by researchers John B. Gurdon and Shinya Yamanaka, for which they won the 2012 Nobel Prize in Medicine, may hold the key to repairing spinal cord injury. They found a way to induce adult cells, like those located in your hair follicles, to become pluripotent. Once this happens, these cells, called induced pluripotent stem cells (iPSCs), can become any cell type in the body.

A team of researchers from Keio University in Japan injected mice that had suffered spinal cord injury with neural cells derived from human iPSCs. These cells were able to successfully migrate and differentiate into their appropriate neural lineages, and they performed synapses. This means that they became exactly the type of cell needed in the place of injury and they successfully communicated with each other.

According to the scientists, compared to the control group, the mice injected with iPSCs had a significantly better functional recovery. The results of this trial, published in Proceedings of the National Academy of Sciences of the United States of America, are a step forward in the path towards eventually promoting complete functional recovery of spinal cord injury in humans.

Once this method is perfected and made available to the public, doctors will need a cell sample that they can turn into neural cells to treat people who suffer from spinal cord injury. It is important to note that the sooner that sample is taken and preserved, the higher its therapeutic potential will be, not only to treat spinal cord injury but many other conditions like Parkinsons, Alzheimers and macular degeneration.This means that the sooner you take action and have your live cells cryopreserved, the better prepared you will be to take advantage of the revolution of regenerative medicine that is coming. To learn more about the ways you can have your cells banked at Acorn, click here.

See original here:
Repairing damage caused by spinal cord injury with stem cells

Spinal Cord Stem Cells commento

Comments Off | data

August 12th, 2020

Implanted Neural Stem Cell Grafts Show Functionality in …

By daniellenierenberg

Colorized scanning electron micrograph of a cultured human neuron. Photo credit: Thomas Deerinck, UC San Diego National Center for Microscopy and Imaging

In a new study, published August 5, 2020 in Cell Stem Cell, researchers at University of California San Diego School of Medicine report successfully implanting highly specialized grafts of neural stem cells directly into spinal cord injuries in mice, then documenting how the grafts grew and filled the injury sites, integrating with and mimicking the animals existing neuronal network.

Although previous research, including published work by Tuszynski and colleagues, had shown improved functioning in SCI animal models after neural stem cell grafts, scientists did not know exactly what was happening.

Co-authors of the study are Kohel J. Sekiguchi and Axel Nimmerjahn, Salk Institute for Biological Studies and Yoshio Takashima, UC San Diego and Veterans Administration Medical Center, San Diego.

Original post:
Implanted Neural Stem Cell Grafts Show Functionality in ...

Spinal Cord Stem Cells commento

Comments Off | data

August 12th, 2020

Stem Cell Banking Market Applications, Types and Future Outlook Report 2020-2025 – Express Journal

By daniellenierenberg

According to latest research report on Global Stem Cell Banking Market report provides information related to market size, production, CAGR, gross margin, growth rate, emerging trends, price, and other important factors. Focusing on the key momentum and restraining factors in this market, the report also provides a complete study of future trends and developments in the market.

The Stem Cell Banking report contains all the details of the expected market dynamics and new market opportunities due to the COVID-19 outbreak. Stratagem Market Insights tried to cover all the market analysis of annual economic growth in the latest report on the Stem Cell Banking market.

According to analysts, the growth of the Stem Cell Banking market will have a positive impact on the global platform and will witness gradual growth over the next few years. This report study incorporates all the market growth and restraining factors along with the important trends mentioned between 2020 and 2025.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/167802

Market segmentation:

The Stem Cell Banking market has been segmented into a variety of essential industries including applications, types, and regions. In the report, each market segment is studied extensively, taking into account market acceptance, value, demand, and growth prospects. Segmentation analysis allows customers to customize their marketing approach to make better orders for each segment and identify the most potential customers.

Global Stem Cell Banking Market Segmentation by Application:

Global Stem Cell Banking Market Segmentation by Product:

Competitive Landscape

This section of the report identifies various major manufacturers in the market. It helps readers understand the strategies and collaborations players are focusing on fighting competition in the marketplace. The comprehensive report gives a microscopic view of the market. The reader can identify the manufacturers footprint by knowing about the manufacturers global revenue, the manufacturers global price, and the manufacturers production during the forecast period.

The major manufacturers covered in this report:

Regional Insights of Stem Cell Banking Market:

In terms of geography, this research report covers almost all major regions around the world such as North America, Europe, South America, Middle East, Africa, and the Asia Pacific. Europe and North America are expected to increase over the next few years. Stem Cell Banking markets in the Asia-Pacific region are expected to experience significant growth during the forecast period. Advanced technology and innovation are the most important characteristics of North America and the main reason why the United States dominates the world market. The Stem Cell Banking market in South America is also expected to expand in the near future.

Years considered for this report:

Important Facts about Stem Cell Banking Market Report:

Questions Answered by the Report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/167802

Read the rest here:
Stem Cell Banking Market Applications, Types and Future Outlook Report 2020-2025 - Express Journal

Bone Marrow Stem Cells commento

Comments Off | data

August 12th, 2020

Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue…

By daniellenierenberg

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2020. The Company's six-month progress includes the development of several strategic initiatives, including growth-oriented opportunities in pain management and COVID-19 related therapeutics.

"Despite the COVID-19 pandemic business disruptions and the near-term delays to completing and commencing our clinical programs in Israel and the U.S., respectively, we acted swiftly over the past few months to leverage our sought-after technology to create several long-term business initiatives to enhance our value," commented Dr. Shai Yarkoni, Chief Executive Officer. "In addition to pursuing a potential merger with a global leader in the high growth medical-grade cannabis market, which is being delayed due to COVID-19, we have either initiated or are contemplating other business development activities that will greatly benefit from our innovation, technology and know-how. I believe each of these opportunities represents meaningful catalysts for Cellect in multi-billion-dollar markets, subject to resolution of the COVID-19 pandemic and return to normal course of business."

Notwithstanding the continued delays due to COVID-19, the Company remains focused on the following operational and clinical objectives:

The Company's cash and cash equivalents totaled $7 million as of June 30, 2020, which includes the approximately $1.5 million (gross before expenses)resulting from several investors exercising certain warrants that were issued in February 2019.

SecondQuarter 2020 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2020 (U.S. $1 = NIS 3.466).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd.

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

2020

2019

2020

2019

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

837

2,901

7,086

1,364

3,564

General and administrative expenses

1,356

4,703

5,064

2,116

2,709

Operating loss

2,193

7,604

12,150

3,480

6,273

Financial expenses (income) due to warrants exercisable into shares

1,098

3,807

(7,111)

4,697

(5,919)

Other financial expenses (income), net

(15)

(55)

880

627

462

Total comprehensive loss

3,276

11,356

5,919

8,804

816

Loss per share:

Basic and diluted loss per share

0.010

0.034

0.029

0.024

0.004

Weighted average number of shares outstanding used to compute basic and diluted loss per share

338,182,275

200,942,871

365,428,101

224,087,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

Convenience

translation

June 30,

December 31,

2020

2019

Unaudited

Audited

U.S. dollars

NIS

(In thousands, except share and per

share data)

CURRENT ASSETS:

See the article here:
Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue...

Bone Marrow Stem Cells commento

Comments Off | data

August 12th, 2020

Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry – PRNewswire

By daniellenierenberg

DUBLIN, Aug. 11, 2020 /PRNewswire/ -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.

Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its off-the-shelf iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.

iPS Cell Commercialization

Methods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand. iPSC cell applications include, but are not limited to:

Since the discovery of iPSC technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.

Key Topics Covered:

1. Report Overview

2. Introduction

3. History of Induced Pluripotent Stem Cells (IPSCS)

4. Research Publications on IPSCS

5. IPSCS: Patent Landscape

6. Clinical Trials Involving IPSCS

7. Funding for IPSC

8. Generation of Induced Pluripotent Stem Cells: An Overview

9. Human IPSC Banking

10. Biomedical Applications of IPSCS

11. Other Novel Applications of IPSCS

12. Deals in the IPSCS Sector

13. Market Overview

14. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/kpc95y

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire

IPS Cell Therapy commento

Comments Off | data

August 11th, 2020

New Study Presents Cell-based Therapy for MN Diseases or Spinal Cord Disorders – Mirage News

By daniellenierenberg

The spinal cord is a bundle of nerves inside the spine that gives your body structure and support. Spinal cord injuries (SCIs) tend to be devastating and most are permanent. Recent research has shown that motor neuron obtained from skin cells could serve as potential treatments for spinal cord injuries, and thus has received considerable research attention. With this, a new door has been opened for treating not only spinal cord injuries, caused by workplace accidents and car crashes, but also Lou Gehrigs disease, known as amyotrophic lateral sclerosis or ALS.

A research team, led by Professor Jeong Beom Kim and his research team in the School of Life Sciences at UNIST has demonstrated that human fibroblasts can be converted into induced motor neurons (iMNs) by sequentially inducing two transcription factors, POU5F1(OCT4) and LHX3. The research team further investigated the therapeutic effects of iMNs for treating traumatic spinal cord injury using rodent spinal cord injury model. Their findings indicate that the sequential induction of two transcription factors is essential for generating self-renewing iMNICs more efficiently. This method not only ensures large-scale production of pure iMNs, but also facilitates the feasibility of iMNs for SCI treatment.

The spinal cord is responsible for transmitting signals from the brain to the rest of the body, and vice versa. Along with motor and sensory deficits, damage to the spinal cord can cause long-term complications, including limited mobility. Although there are many treatment options available for people with SCI, most of them have adverse side effects that impact therapy. And this is why stem cell (SC) therapies to restore functions of damaged tissues are attracting attention, recently. Among those cells constituting the spinal cord, motor neurons that involved in the regulation of muscle function have emerged as a promising candidate for the stem cell-based therapy for SCIs. Despite these encouraging advances, ethical issue of embryonic stem cells (ESCs) and tumorigenic potential of induced pluripotent stem cells (iPSCs) have impeded their translations into clinical trials.

Figure 1. The experimental scheme for the generation of induced motor neurons (iMNs) from human fibroblasts via sequential transduction of two transcription factors.

To overcome these limitations, Professor Kim and his research team established an advanced direct conversion strategy to generate iMNs from human fibroblasts in large-scale with high purity, thereby providing a cell source for the treatment of SCI. These iMNs possessed spinal cord motor neuronal identity and exhibit hallmarks of spinal MNs, such as neuromuscular junction formation capacity and electrophysiological properties in vitro. Importantly, their findings also show that transplantation of iMNs improved locomotor function in rodent SCI model without tumor formation. According to the research team, This proof-of-concept study shows that our functional iMNs can be employed to cell-based therapy as an autologous cell source. Through this, they resolved the problem of immune rejection, and thus reduce the risk of cancer.

In the study, we succeeded in generating iMNs from human fibroblasts by overexpressing POU5F1(OCT4) and LHX3, says Hyunah Lee (Combined MS/Ph.D program of Life Sciences, UNIST), the first author of the study.

Figure 2. Therapeutic effects of iMNs in rat spinal cord injury model in vivo. (A) The position of hindlimbs in control rat and iMN-transplanted rat after 8 weeks of transplantation. (B) C staining analysis of spinal cords after 8 weeks of transplantation (I; Control, J; iMN-transplanted).

The developed motor nerve cell manufacturing method has the advantage of being capable of mass production. A sufficient amount of cells is required for patient clinical treatment, but the existing direct differentiation technique has limited the number of cells that can be obtained. On the other hand, the method developed by the research team is capable of mass production because it undergoes an intermediate cell stage capable of self-renewal. After injecting the produced cells into the spinal cord injury mice, it was confirmed that the lost motor function is restored and the nerves are regenerated in the damaged spinal cord tissue.

Although further investigation on mechanism responsible for cell fate conversion may be needed, our strategy is a safer and simpler methodology that may provide new insights to develop personalized stem cell therapy and drug screening for MN diseases or spinal cord disorders, says Professor Kim. If combined with SuPine Patch, an adhesive hydrogel patches with the purpose of regenerating the damaged spinal cords, its therapeutic effects will be maximized. He adds, As the incidence of spinal cord injury is high due to industrial accidents, synergistic effects with public hospitals specializing in industrial accidents scheduled to be built in Ulsan should be expected.

This study has been jointly carried out with Professor Kims startup company, SuPine Therapeutics Inc. with the support of the Ministry of SMEs and Startups (MSS). The findings of this research have been published in the 2020 June issue of the online edition of eLife, a renowned academic journal of the European Molecular Biology Organizationl (EMBO).

Journal Reference

Hyunah Lee, Hye Yeong Lee, Byeong Eun Lee, et al., Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model, eLife, (2020).

Excerpt from:
New Study Presents Cell-based Therapy for MN Diseases or Spinal Cord Disorders - Mirage News

Spinal Cord Stem Cells commento

Comments Off | data

August 11th, 2020

How European Startups Have Advanced Cancer T-Cell Therapy in… – Labiotech.eu

By daniellenierenberg

With the help of a huge 66M Series A round last week, the German startup T-knife is developing cancer T-cell immunotherapies with the help of genetically modified mice. However, this is just one of several cancer T-cell therapy startups making advances this year, with other innovations including off-the-shelf treatments and a potential universal cancer therapy.

The rise of Chimeric Antigen Receptor (CAR) T-cell immunotherapy was a major step forward in the treatment of cancer. CAR T-cell therapy consists of bioengineering a patients immune T cells to produce proteins called CARs. These proteins recognize targets on the surface of cancer cells, letting the T-cells destroy them. However, CAR T-cell therapy is also limited against solid tumors since many cancer targets lie within the cancer cells, beyond the reach of the CAR proteins.

In the last few months, European startups have been making advances in T-cell receptor (TCR) T-cell immunotherapies, which could be better than CAR T-cells at hunting down solid tumors. This is because the protein that is genetically modified on TCR T cells the TCR can recognize targets hidden inside cancer cells by scanning a protein on the cell surface called human leukocyte antigen (HLA).

Last week, the Berlin-based T-knife brought TCR T-cell therapies into the spotlight with a huge 66M Series A round. With the proceeds, the startup aims to take a radical approach to developing TCR T-cell therapies.

While most TCR T-cell therapy developers tweak existing human TCRs in their cell therapies, T-knife sources its cancer-hunting TCRs from mice. The firm genetically modifies mice to produce fully humanized T-cell receptors and injects them with human tumor antigens. The immune system of the mice then reacts to the cancer antigens and produces a variety of T-cell receptors. After picking the best cancer-seeking T-cell receptors from the mouse immune system, T-knife then expresses them in the patients T cells to produce the cell therapy.

The mouse immune system is not tolerant of human tumor antigens it sees them like a virus or a pathogen. Thus we can generate a strong immune response in the mice when we immunize them with human tumor antigens, Elisa Kieback, CEO and co-founder of T-knife, told me.

According to Kieback, the companys mouse-derived TCRs can latch onto cancer antigens more strongly and specifically than those of established TCR T-cell therapy biotechs such as Immatics and Adaptimmune. We are letting the mice select the best TCR via a very natural in vivo selection mechanism which means they are less likely to have off-target reactivity, she said.

T-knife exited stealth mode with the Series A round, which was led by the investment firms Versant Ventures and RA Capital Management. The company has already initiated the clinical development of a myeloma treatment and plans to sponsor a solid tumor trial in late 2021.

One drawback of cell therapies based on genetically modifying the patients own T cells is that the process is complex, costly, and must be tailored to each patient. To get around this issue, several European startups have been developing TCR T-cell therapies that use donor immune cells in an off-the-shelf fashion, cutting the costs of the therapy.

One such company is the Norwegian startup Zelluna Immunotherapy, which raised 7.5M in equity funding and grants in June. The company aims to develop a TCR T-cell therapy based on cancer-hunting immune cells called natural killer cells. The company sees these cells as well suited for making off-the-shelf therapies since they have a lower risk of attacking the patients healthy tissue than T cells and are faster at killing cancer cells.

Another off-the-shelf TCR T-cell therapy in the works is being developed by the Dutch biotech Gadeta, which appointed a new CEO in April. It is working with the US company Kite Pharma to engineer T cells that produce TCRs from a rare type of T cell called gamma delta T cells. The TCRs from gamma delta T cells are better at recognizing stress signals on cancer cells than those of the more common type of T cells, called alpha beta T cells.

Gadetas platform combines the key features ofalpha beta T cells, such as the high proliferation and memory capacity, with the anti-tumor specificity and activity of selectedgamma delta receptors, Marco Londei, the companys new CEO, told me. This novel T cell platform is perfectly placed for possible allogeneic off-the-shelf use.

Gadeta is currently preparing to enter phase I testing for the treatment of multiple myeloma.

TC Biopharm has also hinted at promising progress with its own off-the-shelf cancer cell immunotherapy. The Scottish startup collects gamma delta T cells from young, healthy donors and makes them produce CAR proteins like a CAR T-cell therapy.

In some patients, the innate ability to hunt and kill cells is compromised either because of the cancer itself, other pathologies or age, Michael Leek, CEO of TC BioPharm, explained.

This is no ordinary CAR T-cell therapy, however. TC BioPharm also uses the gamma delta T cells TCRs as a safety catch to avoid destroying healthy cells that happen to show a cancer target. The CAR protein recognizes a cancer target on the cell surface, but the gamma delta TCR only allows the cell therapy to kill cells that show signs of stress from cancer. This could make it much safer than current CAR T-cell therapies.

TC BioPharm initiated a phase I clinical trial for the treatment of the blood cancer acute myeloid leukemia last year. The trial has progressed well; all qualifying patients saw a marked response to treatment with reduction of their tumor burden, Leek told me. We hope to progress this therapy to market around 2021-22.

In addition to cancer, TC BioPharm has also joined a growing list of immuno-oncology companies testing the potential of its technology for the treatment of Covid-19, launching a phase I trial in July.

Though TCR T-cell therapies can target more types of cancer than CAR T-cell therapies, they still tend to be specific to particular types of cancers, and ineffective against others. One cancer entity is oftentimes much more heterogeneous than initially thought, Kai Pinkernell, CMO of Munich-based Medigene, told me. Could such a therapy target more than one cancer type?

In June, Medigene initiated a phase I clinical trial of a TCR T-cell therapy candidate for a diverse range of blood cancers. The treatment is designed to hit a target that they all have in common called HA-1. The trial is testing the treatment in patients that recently received a bone marrow stem cell transplant, but whose blood cancer has relapsed.

[Our therapy] would improve the current gold-standard approach, being stem cell transplantation. Interestingly, this could work in many different diseases that were the reason for the transplant, Pinkernell explained.

Another TCR T-cell therapy player aims to go even further with widening the range of treatments. In January, the London-based Ervaxx recently rebranded as Enara Bio entered a partnership agreement with the University of Cardiff to overcome a common limitation of TCR therapies: the HLA molecules that TCRs scan vary widely between patients, so TCR T-cell therapies need to be personalized to different patients.

To get around this obstacle, Enara Bio and a research group led by Andrew Sewell, Professor of Immunology at Cardiff University, are developing a type of TCR T-cell therapy that doesnt scan HLA, but rather a protein called MR1, which is the same from patient to patient and is found on a wide range of cancer cells.

We have various T-cell receptors that respond to most cancers without the need for a specific human leukocyte antigen that we are exploring, Sewell told me.

By accessing a wide range of cancers and patients, this cancer immunotherapy could work universally with no need for personalization. The team aims to test the therapy in humans at the end of this year.

While a universal cancer therapy is an intriguing concept, Pinkernell thinks that we should be cautious in our expectations of seeing such a therapy. The timing of the drug in the therapy of a cancer, or best window of application is not easy to find, he said.

T-knifes Kieback echoed the skepticism. For now, rather highly tumor-, target-, and patient-specific therapies will be required and emerge, she said. Londei of Gadeta agreed and pointed out the complexity of cancer disease development. Key challenges are understanding how tumors escape immunotherapies and how to find combination therapies to overcome this problem, for different types of tumors, he added.

Sewell has a slightly more optimistic take. I think it is a bit strong to say that there is potential for universal therapies, but we can definitely build T cells that recognize most cancers from all individuals. I feel that there is a prospect for immunotherapy to be successfully treating most cancers within the next 25 years.

Part of the reason for the unclear potential of TCR T-cell therapy is that it is at an early stage in the clinical pipeline. The most advanced TCR T-cell therapy programs havent yet gone beyond phase II, such as that of Adaptimmunes lead candidate. However, the size of T-knifes recent Series A round demonstrates that investors are interested in the future of the technology, so its going to be worth keeping an eye on the TCR T-cell startup scene in the coming years.

Images from Shutterstock

Follow this link:
How European Startups Have Advanced Cancer T-Cell Therapy in... - Labiotech.eu

Bone Marrow Stem Cells commento

Comments Off | data

August 11th, 2020

Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – Good Night, Good Hockey

By daniellenierenberg

Stem Cell Therapy Market is expected to reach 202.77 billion by 2026 from XX billion in 2018 at CAGR of XX %.REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/522

Stands for use of stem cells to treat or prevent disease or condition.Bone marrow transplant and some therapies derived from umbilical cord blood are mainly used in stem cell therapy. Advancement, in order to establish new sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions, are increased in recent years.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Stem Cell Therapy Market Researchers are making efforts to discover novel methods to create human stem cells. This will increase the demand as well as supply for stem cell production and potential investigation in disease management. Increasing investment & research grants for developing safe and effective stem cell therapy products, the growing patient base for target diseases, concentrated product pipelines, increasing approval of the new clinical trials, rapid technological advancement in genomics, and the rising awareness about the stem cell are expected to drive the growth of the Stem Cell Therapy solutions market during the forecast period.

However, improper infrastructure, insufficient storage systems, nascent technology in underdeveloped economies, Ethical issues related to an embryonic stem cell, low patient acceptance rate, Difficulty in the preservation of stem cell are expected to restrain the market growth. North America is expected to be the largest growing region by 2026; the reason behind that is extensive funding by Government. However, Emerging countries like India, china, Korea have low growth rate as compared to Developed regions in 2017 but increase in awareness about stem cell therapy will lead the Asia Pacific to generate a significant level of revenue by 2026.

Key Highlights of Stem Cell Therapy Market report

Detailed quantitative analysis of the current and future trends from 2017 to 2026, which helps to identify the prevailing market opportunities.Comprehensive analysis of factors instrumental in changing the market scenario, rising prospective opportunities, market shares, core competencies in terms of market development, growth strategies and identification of key companies that can influence this market on a global and regional scale.Assessment of Market definition along with the identification of key drivers, restraints opportunities and challenges for this market during the forecast period.Complete analysis of micro-markets with respect to individual growth trends, prospects, and contributions to the overall Stem Cell Therapy Solutions market.Stem Cell Therapy market analysis and comprehensive segmentation with respect to the Application, End users, Treatment, and geography to assist in strategic business planning.Stem Cell Therapy market analysis and forecast for five major geographies-North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions.For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a global market value for the stem cell therapy market.Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Key Target Audience:

Stem Cell Associations and OrganizationsGovernment Research Boards and OrganizationsResearch and consulting firmsStem Cell Therapy Market InvestorsHealthcare Service Providers (including Hospitals and Diagnostic Centers)Stem Cell Therapeutic Product Manufacturing OrganizationsResearch LabsClinical research organizations (CROs)Stem Cell Therapy Marketing PlayersPharmaceutical Product Manufacturing CompaniesScope of the Stem Cell Therapy Market Report:

Stem Cell Therapy market research report categorizes the Stem Cell Therapy market based on Application, End users, Treatment, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Stem Cell Therapy market with key developments in companies and market trends.Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Available Customization:

With the given market data, Maximize Market Research offers customization of report and scope of the report as per the requirement

Regional Analysis:

Breakdown of the North America stem cell therapy marketBreakdown of the Europe stem cell therapy marketBreakdown of the Asia Pacific stem cell therapy marketBreakdown of the Middle East & Africa stem cell therapy marketBreakdown of the Latin America stem cell therapy market

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Excerpt from:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Good Night, Good Hockey

Bone Marrow Stem Cells commento

Comments Off | data

August 11th, 2020

Covid-19 Impact on Global Orthopedic Regenerative Medicine Market Rapid Growth By 2019 2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika…

By daniellenierenberg

Latest released the research study on Global Orthopedic Regenerative Medicine Market, offers a detailed overview of the factors influencing the global business scope. Orthopedic Regenerative Medicine Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Orthopedic Regenerative Medicine. The study covers emerging players data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Definition:

Orthopedic Regenerative Medicine strategy sends messages to the customers or subscribers in predefined schedule. However, other forms of media can also be used in Orthopedic Regenerative Medicine. It is the most common form of marketing as multiple messages can be sent in low costs. Orthopedic Regenerative Medicine is used to achieve business objectives such as increasing sales, maintaining communications with customers while saving the business time. Moreover, the users can personalize each of the email messages and increase conversion rate.

Market Drivers

Market Trend

Opportunities

Challenges

Detailed Segmentation:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Analyst at CMI have conducted special survey and have connected with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to fight the situation. A special chapter in the study presents Impact Analysis of COVID-19 on Global Orthopedic Regenerative Medicine Market along with tables and graphs related to various country and segments showcasing impact on growth trends.

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Download PDF Brochure of Research Report @https://www.coherentmarketinsights.com/insight/request-pdf/3566

Strategic Points Covered in Table of Content of Global Orthopedic Regenerative Medicine Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Orthopedic Regenerative Medicine market

Chapter 2: Exclusive Summary the basic information of the Orthopedic Regenerative Medicine Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Orthopedic Regenerative Medicine

Chapter 4: Presenting the Orthopedic Regenerative Medicine Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2014-2019

Chapter 6: Evaluating the leading manufacturers of the Orthopedic Regenerative Medicine market which consists of its Competitive Landscape, Peer Group Analysis

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2019-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Orthopedic Regenerative Medicine Market is a valuable source of guidance for individuals and companies in decision framework.

Data Sources & Methodology

The primary sources involves the industry experts from the Global Orthopedic Regenerative Medicine Market including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Companys Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

Get Discount on This Premium Report @https://www.coherentmarketinsights.com/insight/request-discount/3566

What benefits does CMI research study is going to provide?

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

About Author:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

Mr Raj ShahCoherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone +1-206-701-6702sales@coherentmarketinsights.com

See the rest here:
Covid-19 Impact on Global Orthopedic Regenerative Medicine Market Rapid Growth By 2019 2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika...

Bone Marrow Stem Cells commento

Comments Off | data

August 11th, 2020

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, MD, to Investigate Proprietary T-Cell Therapy for Treatment of…

By daniellenierenberg

METUCHEN, N.J., Aug. 10, 2020 /PRNewswire/ --Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expertNeal Flomenberg, M.D., Professor and Chair of the Department of Medical Oncology at Thomas Jefferson University, with the intent to evaluate Tevogen' s proprietary antigen-specific T cell technology as a potential treatment for COVID-19 and influenza-A patients.

This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise and research prowess to investigate potential treatments for viral infections.

Dr. Flomenberg has been at the forefront of immunogenetics and immunology for more than four decades. "Tevogen's technology resonated with me as there have been several groups who have used T cells to treat patients after bone-marrow transplants. The idea of utilizing T cell therapies to potentially treat COVID-19 and other viruses is truly remarkable," Flomenberg said. "I'm enthusiastic about moving forward with an investigation of Tevogen's technologies."

Tevogen CEO Ryan Saadi, M.D., M.P.H., is leading the new biotech's efforts. "Our work has been to pioneer T cell therapies that can be abundantly and efficiently reproduced to develop an affordable and scalable cellular treatment for the biggest global health threats, including COVID-19, influenza, and a variety of cancers. We are very excited about Dr. Flomenberg's contribution to our efforts and hope to initiate our investigational study soon."

In addition to developing its potential therapies, Tevogen is committed to organizational and manufacturing efficiency. This should allow it to engage in affordable innovation to the benefit of all patients.

About Tevogen Bio

Tevogen Bio was formed after decades of research by its contributors to concentrate and leverage their expertise, spanning multiple sectors of the health care industry, to help address some of the most common and deadly illnesses known today. The company's mission is to provide curative and preventative treatments that are affordable and scalablein order to positively impact global public health.

About Dr. Neal Flomenberg

Dr. Neal Flomenberg is the Chairman of Medical Oncology at Jefferson University in Philadelphia and also heads the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Program. Throughout his more than four decades of practice, he has maintained a longstanding interest in the immunogenetics and immunology of stem cell transplantation, with the goal of making transplantation safer and more widely available. Dr. Flomenberg developed an approach to bone-marrow transplants that uses half-matched relatives as donors, a breakthrough that assures that the majority of blood and bone-marrow cancer patients can benefit from this potentially curative treatment.

Media Contacts:

Mark Irion[emailprotected]

Katelyn Petroka [emailprotected]

SOURCE Tevogen Bio

Bone Marrow Stem Cells commento

Comments Off | data

August 10th, 2020

Boy, 4, may look fighting fit but only has months to live – unless you can save him – Mirror Online

By daniellenierenberg

His name means brave in Hindi. And for four year-old Veer Gudhka that couldnt be more appropriate.

For while the bubbly little boy might look fighting fit, he actually has just months to live.

Veer suffers from a rare blood disorder called Fanconi anaemia, which results in a decreased production of all types of blood cells.

But a stem cell donor will save his life.

In a heartfelt video message, the plucky toddler asks Sunday Mirror readers: Please be my life-saver? Will you be my superhero?

And today his family are appealing to those from BAME communities to help by signing up to the Anthony Nolan stem cell register.

Mum Kirpa and dad Nirav know the odds are stacked against them getting that all-important call because they are of Indian descent.

While 69 per cent of Northern European patients find the best possible stem cell match from a stranger, this drops to just 20 per cent for those with black, Asian or ethnic minority backgrounds.

Currently only two per cent of the population is on the UK stem cell register.

And with Asians making up just six per cent of the UK population, there is a smaller pool of potential donors.

Veer was diagnosed with the blood disorder last August, after he started suffering from extreme fatigue, and was referred for tests.

Doctors said he would need a stem cell transplant within three years for a chance of survival.

They hoped to buy Veer some time by putting him on steroids to boost his blood counts. But his condition has deteriorated fast.

Recent tests at Great Ormond Street Hospital in London show he now has just three to four months to find a donor.

Kirpa and Nirav were both tested, along with Veers six-year-old sister Suhani, but none of them were a match.

A search on the global stem cell register also drew a blank.

And his dad has been trying to encourage his fellow countrymen and women in India to join the register.

They have even signed up a female battalion of the Indian Army.

Kirpa, 37, from Harrow, London, said: We just feel so scared were going to lose our cheeky, amazing little boy. To look at Veer you wouldnt know hes critically ill.

Like his name, hes been brave from the start. Hes undergone countless tests and hospital visits but has had a constant smile on his face.

"He knows he needs a superhero to step forward, but his optimism and enthusiasm are infectious and keep us all going.

She added: Going on the register is incredibly quick and donating cells if you match someone in need is painless.

You can join the Anthony Nolan stem cell register today.

Nine out of 10 people donate their stem cells through the bloodstream in a simple IV process called peripheral blood stem cell collection.

One in 10 will have their stem cells collected via the bone marrow itself, while under general anaesthetic. Doctors transplant the new, healthy cells via the patients bloodstream, where they begin to grow and create healthy red blood cells, white blood cells and platelets.

A perfect match from a donor can mean a lifelong cure.

Veers dad Nirav, 40, said: I only learned about the Anthony Nolan stem cell register two years ago and even then I assumed it would involve long and painful procedures.

We need to raise awareness to save lives in every community.

Read the rest here:
Boy, 4, may look fighting fit but only has months to live - unless you can save him - Mirror Online

Bone Marrow Stem Cells commento

Comments Off | data

August 10th, 2020

Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. – Good Night, Good…

By daniellenierenberg

Global Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Cell Therapy Technologies Market: Overview

Cell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: Drivers and Restraints

The growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation Analysis

On the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional Analysis

North America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

More:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. - Good Night, Good...

Bone Marrow Stem Cells commento

Comments Off | data

August 10th, 2020

T cells, B cells and the range of the human bodys immune response A simple decoder – ThePrint

By daniellenierenberg

Text Size:A- A+

New Delhi: Human immunity and its components have never been the topic of such breathless discussion for such a long time. But then, there has never been a time like the Covid-19 pandemic.

Between serological surveys (that check the level of antibodies against the SARS-CoV-2 virus in blood), rapid antigen tests (that test for the part of the virus that kickstarts immune mechanisms) and the quest for vaccines, the immune system is very much in.

That is also why lymphocytes (a class of white blood cells), especially the ones known as T-cells are the flavour of the season. They are probably the single most important component of the immune system; though given the perfectly synchronised working of the defence mechanism of the body, it may be a little unfair to designate any one as more important than the another.

T-cells play a plethora of roles in immunity as killer cells that can attack an infected cell and kill it along with the infecting agent, and as suppressor cells that modulate the level of functioning of other lymphocytes. They also have a starring role in the production of antibodies, a function performed by the other variant of lymphocytes called the B cells.

Latest research in Nature shows that presence of T-cells from earlier encounters with coronaviruses could have an important role to play in the bodys immune response, and therefore, a better understanding of it is crucial for the development of a vaccine.

The published data discussed here indicate that patients with severe COVID-19 can have either insufficient or excessive T cell responses. It is possible, therefore, that disease might occur in different patients at either end of this immune response spectrum, in one case from virus-mediated pathology and in the other case from T cell-driven immunopathology.

However, it is unclear why some patients respond too little and some patients too much, and whether the strength of the T cell response in the peripheral blood reflects the T cell response intensity in the respiratory tract and other SARS-CoV-2-infected organs, wrote the researchers from the University of Pennsylvania. They called for more research on the topic.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

Turns out, antibodies may or may not last, but T-cells are the new superheroes with the potential to possibly save the planet.

Also read: T Cells the unsung immune warriors that takeover after coronavirus antibodies wane

Immunity is of two kinds innate and acquired.

The defence mechanisms that the body is born with is known an innate immunity. This includes something as simple as the ability of the skin to prevent inner, more vulnerable tissues, from coming in contact with the external environment.

Acquired immunity, as the name suggests, is something that develops over time through exposure to pathogens or disease causing agents like virus and bacteria. Acquired immunity kicks in either through antibodies (this is known as humoral immunity) or through cells programmed to destroy invading organisms by causing the dissolution of the very cells that have been infected.

White blood cells (WBC) play a crucial role in immunity. There are five different kinds of WBCs eosinophil, basophil, neutrophil, monocyte and lymphocyte. Among these, the most important are lymphocytes, which include the T lymphocytes and the B lymphocytes. However, the others also have important roles to play as supporting cast. For the present discussion, we are concentrating on lymphocytes.

Also read: Immunity boosters are a myth why you shouldnt believe claims that promise to fight Covid

Structurally, under a microscope, very little differentiates a T-lymphocyte from a B lymphocyte. Both varieties are formed in the bone marrow from stem cells, get trained in different organs and then lodge themselves in the lymph nodes from where they are deployed when the occasion arises.

The training is important. It teaches the cells not to start attacking the bodys own cells. T-cells get trained antenatally (during pregnancy) and for some time after that in the thymus, a small gland present between the lungs only till puberty. B cells are trained in the foetal liver and bone marrow.

When a pathogen invades, specific chemicals unique to it (often proteins or complex carbohydrates) activate the bodys immune system. This activator, which is a unique feature of the invading pathogen, is the antigen. This is what the rapid antigen test looks for.

When an antigen has been detected, the T-cells troop out of the lymph node in an activated form and travel to the affected areas to take on the infection. The activated cells, called the Killer T cells, attach themselves to the membrane of the infected cell and with help of cytotoxic chemicals, kill the cell and destroy the invader with it. This is cell-mediated immunity. It is the basis of what happens when transplanted organs are rejected.

The thymus training teaches T-cells to ignore the antigens that are present within the body and not attack them. When that lesson is forgotten, because of genetic or environmental reasons, an autoimmune disorder is triggered.

Antigens set in motion a different pathway in the B lymphocytes. These enlarge and start duplicating very rapidly to form many clones, all of which, on maturity, start producing antibodies. The whole process happens very fast.

Antibodies are protein molecules that are present in the plasma, the matrix of the blood in which the cells float. Not all T-cells though turn into cytotoxic killers. Some become what are known as helper T cells, to go and further activate B lymphocytes to produce antibodies. In fact, without these helper cells, the antibody output is not quite sufficient to combat the invading particle.

Antibodies can directly kill the invader using a number of different mechanisms at their disposal. They can also activate a set of proteins present in the blood plasma that in turn can attack the invader using their own pathways.

Once the infection has been tackled, some of the B lymphocytes are tucked away with information about how this was done. These are memory cells that remain dormant until the next invasion happens. These ensure that when an infection recurs, the response is expedited, magnified and is longer lasting. This is the principle behind vaccination to teach the body to identify and combat a pathogen so that when a future infection happens, the response is stronger.

Also read:An Oxford immunologist breaks down how the universitys vaccine works against Covid-19

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

Here is the original post:
T cells, B cells and the range of the human bodys immune response A simple decoder - ThePrint

Bone Marrow Stem Cells commento

Comments Off | data

August 10th, 2020

Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. – Good Night, Good Hockey

By daniellenierenberg

Global Multiple Myeloma Treatment Marketsize was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 11.34% from 2019 to 2027, reaching nearly US$ XX Mn.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Multiple myeloma, also known as Kahlers disease, is a type of blood cancer of plasma cells that are found in the bone marrow. Multiple myeloma causes cancer cells to accrue in the bone marrow, where they attack the strong blood cells.

Multiple myeloma treatments have developed significantly above the last decade. New multiple myeloma treatments have provided efficient survival rates between myeloma patients. It has been also observed that the future drug pipeline of multiple myeloma is promising, biological drugs and stem cell-based therapies are likely to fuel the multiple myeloma treatment market in the upcoming years. On the other hand, the costs of radiotherapeutic equipment implementation, a limited number of target patients population, strict legal regulations are expected to hamper the market growth. Likewise, the MMR report contains a detailed study of factors that will drive and restrain the growth of the multiple myeloma treatment market globally.

Multiple Myeloma accounts for approximately 2.5% of the cancer-related deaths globally and is the second most major type of blood cancer next to Hodgkins Lymphoma. According to the World Cancer Research Fund, in 2018, above 159500 cases of multiple myeloma were diagnosed with the condition, where the occurrence rate among women and men was found in the ratio 1.2:1. The onset of the disease occurs after the age of 60. In recent times, the age of onset is drastically decreasing. In the year 2001, only two medications were available for treating multiple myeloma but now in 2020, 18 medicines are available. Moreover, there are over 25 FDA-approved drugs for treating multiple myeloma with therapeutics such as pomalidomide, carfilzomib, panobinostat, and ixazomib. The availability of new medications has given new hope for better treatments and better results and thus affecting the growth of the market as well. However, the survival of patients with a limited response while receiving treatment with primary immunodeficiency therapy remains poor and is one of the major challenges.

The MMR report covers the segments in the multiple myeloma treatment market such as type and application. By application, the hospital is expected to continue to hold the largest XX.85% share in multiple myeloma treatments market thanks to growing specialist doctors providing the best chance of long term survival.

North Americas multiple myeloma treatments market was valued at US$ XX.26 Mn. in 2019 and is expected to reach a value of US$ XX.13 Mn. by 2027, with a CAGR of 9.3%. The number of patients in the U.S is growing YoY with nearly 14600 new cases diagnosed annually. In 2017 alone there were approximately 142000 patients diagnosed for multiple myeloma.

Europe and the South African population are prone to develop multiple myeloma when compared with Asian economies. Though, the population in the APAC region outwits Europe and Africa. Further, growing the adoption rate of novel therapies, coupled with the support from the government along with non-government organizations and improving the survival of multiple myeloma patients.

The research study includes the profiles of leading players operating in the global multiple myeloma treatment market. Eli Lilly Company acquired ARMO Biosciences to develop immunotherapies for the treatment of cancer, hypercholesterolemia, inflammatory, and fibrosis diseases.

The objective of the report is to present a comprehensive analysis of the Global Multiple Myeloma Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Multiple Myeloma Treatment Market dynamics, structure by analyzing the market segments and projects the Global Multiple Myeloma Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Multiple Myeloma Treatment Market make the report investors guide.Scope of the Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market, by Applications

Hospitals Clinics Cancer Treatment and Rehabilitation CentersGlobal Multiple Myeloma Treatment Market, by Type

Proteasome Inhibitors Immunomodulatory Agents (IMiDs) Histone Deacetylase (HDAC) Inhibitors Immunotherapy Cytotoxic ChemotherapyGlobal Multiple Myeloma Treatment Market, by Region

Asia Pacific North America Europe South America Middle East & AfricaKey players operating in Global Multiple Myeloma Treatment Market

Celgene Corporation Janssen Biotech, Inc. Bristol-Myers Squibb Company Novartis AG Cellectar Biosciences Inc. Millennium Pharmaceuticals Amgen, Inc. bbVie Genzyme Corporation Juno Therapeutics Eli Lilly and Company Glenmark Pharma

Global Multiple Myeloma Treatment Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/65671About Us:

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: sales@maximizemarketresearch.comContact: +919607065656 / +919607195908Website:www.maximizemarketresearch.com

Link:
Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. - Good Night, Good Hockey

Bone Marrow Stem Cells commento

Comments Off | data

August 10th, 2020

Next Page · Previous Page

Page 273«..10 20..272273274 275..280 290..»

Skin Disorders: Pictures, symptoms, causes and help – TODAY – TODAY

By daniellenierenberg

IN CASE YOU MISSED ITSchedule of Reuters features from this week – Reuters

By daniellenierenberg

Back From the Dead? Stem Cells Give Hope for Revival of Malaysia’s Extinct Rhinos – The New York Times

By daniellenierenberg

Beauty & Wellness Awards 2020: New Kids on the Block – Prestige Online

By daniellenierenberg

Going On At The Greenville Library – WSPA 7News

By daniellenierenberg

Stem Cell Grafts Show Functionality in Spinal Cord Injuries

By daniellenierenberg

Repairing damage caused by spinal cord injury with stem cells

By daniellenierenberg

Implanted Neural Stem Cell Grafts Show Functionality in …

By daniellenierenberg

Stem Cell Banking Market Applications, Types and Future Outlook Report 2020-2025 – Express Journal

By daniellenierenberg

Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue…

By daniellenierenberg

Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry – PRNewswire

By daniellenierenberg

New Study Presents Cell-based Therapy for MN Diseases or Spinal Cord Disorders – Mirage News

By daniellenierenberg

How European Startups Have Advanced Cancer T-Cell Therapy in… – Labiotech.eu

By daniellenierenberg

Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – Good Night, Good Hockey

By daniellenierenberg

Covid-19 Impact on Global Orthopedic Regenerative Medicine Market Rapid Growth By 2019 2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika…

By daniellenierenberg

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, MD, to Investigate Proprietary T-Cell Therapy for Treatment of…

By daniellenierenberg

Boy, 4, may look fighting fit but only has months to live – unless you can save him – Mirror Online

By daniellenierenberg

Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. – Good Night, Good…

By daniellenierenberg

T cells, B cells and the range of the human bodys immune response A simple decoder – ThePrint

By daniellenierenberg

Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. – Good Night, Good Hockey

By daniellenierenberg

Categories

Archives

Recommended Sites